Pulmonary Therapy

Aims & Scope

Pulmonary Therapy is an international, open access, peer-reviewed (single-blind), and rapid publication journal.

The scope of the journal is broad and will consider all scientifically sound research from pre-clinical, clinical (all phases), observational, real-world, and health outcomes research around the use of pulmonary therapies, devices, and surgical techniques.

Areas of focus include, but are not limited to: asthma; chronic obstructive pulmonary disease; idiopathic pulmonary fibrosis; pulmonary hypertension; cystic fibrosis; lung cancer; respiratory tract disorders; allergic rhinitis and other respiratory allergies; influenza, pneumococcal infection, respiratory syncytial virus and other respiratory infections; and inhalers and other device therapies.

The journal is of interest to a broad audience of pharmaceutical and healthcare professionals and publishes original research, reviews, case reports/series, trial protocols and short communications such as commentaries and editorials.

Pulmonary Therapy will consider all scientifically sound research be it positive, confirmatory or negative data.

Submissions are welcomed whether they relate to an international and/or a country-specific audience, something that is crucially important when researchers are trying to target more specific patient populations.

This inclusive approach allows the journal to assist in the dissemination of quality research, which may be considered of insufficient interest by other journals.

Metrics & Ranking

Abstracting & Indexing

Journal is indexed in leading academic databases, ensuring global visibility and accessibility of our peer-reviewed research.

• Scopus
• Google Scholar
• Directory of Open Access Journals (DOAJ)
• Web of Science
• Embase

Subjects & Keywords

Journal’s research areas, covering key disciplines and specialized sub-topics in Health Professions and Medicine, designed to support cutting-edge academic discovery.

Licensing & Copyright

This journal operates under an Open Access model. Articles are freely accessible to the public immediately upon publication. The content is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0), allowing users to share and adapt the work with proper attribution.

Copyright remains with the author(s), and no permission is required for non-commercial use, provided the original source is cited.

Policy Links

This section provides access to essential policy documents, guidelines, and resources related to the journal’s publication and submission processes.

• Aims scope
• Homepage
• Oa statement
• Author instructions
• License terms
• Review url
• Board url
• Copyright url
• Plagiarism url
• Preservation url
• Apc url
• License

Plagiarism Policy

This journal follows a plagiarism policy. All submitted manuscripts are screened using reliable plagiarism detection software to ensure originality and academic integrity. Authors are responsible for proper citation and acknowledgment of all sources, and any form of plagiarism, including self-plagiarism, will not be tolerated.

For more details, please refer to our official: Plagiarism Policy.

APC Details

The journal’s Article Processing Charge (APC) policies support open access publishing in Health Professions and Medicine, ensuring accessibility and quality in research dissemination.

This journal requires an Article Processing Charge (APC) to support open access publishing, covering peer review, editing, and distribution. The current APC is 5,500.00 EUR. Learn more.

Explore journals without APCs for alternative publishing options.

Most Cited Articles

The Most Cited Articles section features the journal's most impactful research, based on citation counts. These articles have been referenced frequently by other researchers, indicating their significant contribution to their respective fields.

• Severe Asthma and Biological Therapy: When, Which, and for Whom

  Citation: 72

  Authors: Paola, Luigino, Maria Gabriella, Rossella, Beatrice Ludovica, Nicola A., Mario

• Digital Inhalers for Asthma or Chronic Obstructive Pulmonary Disease: A Scientific Perspective

  Citation: 64

  Authors: Amy H. Y., Roy A., Rajiv, Stephen L., Stephen A., Richard W., Rajan

• A Review on the Safety and Efficacy of Inhaled Corticosteroids in the Management of Asthma

  Citation: 63

  Authors: Qian, Xiao-Ou, Anthony

• In-Vitro Characterization of the Aerosolized Dose During Non-Invasive Automatic Continuous Positive Airway Pressure Ventilation

  Citation: 61

  Authors: Ahmed, Hoda, Raghda R. S., Randa, Maha M., Amira S. A., Heba F., Mohamed E.

• Post-COVID-19 Pulmonary Fibrosis: Facts—Challenges and Futures: A Narrative Review

  Citation: 60

  Authors: Sy, Thu, Quynh, Tuan, Tinh, Quan, Vinh

• Identification of Asthma Subtypes Using Clustering Methodologies

  Citation: 59

  Authors: Matea, Matthew, Danielle, Adnan

• Diagnosis and Management of Pulmonary Hypertension in the Modern Era: Insights from the 6th World Symposium

  Citation: 49

  Authors: Christopher A., Ryan J., David F., Vinicio A.

• Potential Benefit of Repeated Dry Powder Inhaler’s Inhalation Technique Counseling on Asthmatic Patients

  Citation: 43

  Authors: Marwa O., Mohamed E., Randa Salah

• Treatment of Persistent Cough in Subjects with Idiopathic Pulmonary Fibrosis (IPF) with Gefapixant, a P2X3 Antagonist, in a Randomized, Placebo-Controlled Clinical Trial

  Citation: 41

  Authors: Fernando J., Amna Sadaf, Jaclyn A., Anthony P., Jerry Jing, Yuping, Michael M., Iftikhar, Mandel, Selwyn, Faisal, Mark, Kevin, Lisa, Maureen, Robert, Kapil, Mary Beth, Robert, Ganesh, Imre, Michael, Shahzad, Neil, Vivek, Murali

• Ex Vivo Lung Perfusion: A Review of Current and Future Application in Lung Transplantation

  Citation: 41

  Authors: Kareem, Jennifer L., A. Whitney